Full text
Earnings transcript
Read the complete earnings call transcript.
NEOG
Neogen Corporation
$9.29
0.22
(2.43%)
| Exchange: | NASDAQ |
| Market Cap: | 2.022B |
| Shares Outstanding: | 20.615M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Mikhael Nassif | |||||
| Full Time Employees: | 2917 | |||||
| Address: |
| |||||
| Website: | https://www.neogen.com |
Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 822,447 | 924,222 | 894,661 |
| Gross Profit | 405,955 | 462,635 | 421,376 |
| EBITDA | 122,296 | 182,597 | -937,754 |
| Operating Income | 37,515 | 77,426 | 9,420 |
| Net Income | -22,870 | -9,421 | -1,092,044 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 4,554,432 | 4,548,833 | 3,443,836 |
| Total Liabilities | 1,420,215 | 1,404,691 | 1,372,582 |
| Total Stockholders Equity | 3,134,217 | 3,144,142 | 2,071,254 |
| Total Debt | 900,000 | 906,239 | 894,111 |
| Cash and Cash Equivalents | 163,240 | 170,611 | 129,004 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 41,028 | 35,264 | 58,244 |
| Capital Expenditure | -65,757 | -111,421 | -104,595 |
| Free Cash Flow | -24,729 | -76,157 | 58,244 |
| Net Income | -22,870 | -9,421 | -1,092,044 |
| Net Change in Cash | 118,767 | 7,371 | -41,607 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 808,467.670 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 848,365.632 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 831,900 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -49,033.870 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -46,727.846 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -48,082.188 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 104,476.086 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 111,238.867 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 108,447.431 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 301,278.642 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 316,146.774 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 310,010.792 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.510 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.480 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Revenue Performance: Neogen Corporation reported strong second-quarter revenue for FY 2026, as highlighted in the earnings call transcript, reflecting consistent demand for its products and services within the industry. This aligns with historical revenue data from income statements, indicating a stable growth trajectory.
- Operational Efficiency: The earnings call summary emphasizes improvements in core operations, with a focus on enhancing profitability. Key metrics such as gross profit margin (TTM) and operating income from income statements support a positive trend in cost management and operational effectiveness.
- Strong Balance Sheet Metrics: Balance sheet data shows a healthy level of cash and cash equivalents alongside manageable total liabilities, providing financial flexibility for future investments or debt servicing, as reflected in a reasonable debt-to-equity ratio (TTM).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about NEOG valuation
Is Neogen Corporation (NEOG) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Neogen Corporation (NEOG) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is NEOG a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NEOG trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is NEOG’s P/E ratio?
You can see NEOG’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for NEOG?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is NEOG a good long-term investment?
Whether NEOG fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
NEOG
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.43
Trading Metrics:
| Open: | 9.2 | Previous Close: | 9.07 | |
| Day Low: | 8.99 | Day High: | 9.4 | |
| Year Low: | 4.56 | Year High: | 11.43 | |
| Price Avg 50: | 9.16 | Price Avg 200: | 7.96 | |
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
NEOG Q3 Earnings & Revenues Top, Gross Margin Down, Stock Crashes
